Insulet Co. (NASDAQ:PODD) Shares Purchased by Captrust Financial Advisors

Captrust Financial Advisors raised its stake in shares of Insulet Co. (NASDAQ:PODD) by 24.1% during the fourth quarter, HoldingsChannel reports. The fund owned 2,185 shares of the medical instruments supplier’s stock after acquiring an additional 425 shares during the quarter. Captrust Financial Advisors’ holdings in Insulet were worth $570,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in PODD. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. acquired a new position in Insulet in the fourth quarter worth about $42,000. SRS Capital Advisors Inc. increased its holdings in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 56 shares during the last quarter. Assetmark Inc. increased its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Insulet by 117.3% during the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $72,000 after buying an additional 149 shares in the last quarter.

Insiders Place Their Bets

In related news, SVP John W. Kapples sold 5,278 shares of the business’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president now owns 23,180 shares of the company’s stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Trading Up 0.8%

Insulet stock opened at $324.75 on Monday. The firm has a 50-day moving average price of $264.14 and a two-hundred day moving average price of $266.94. Insulet Co. has a 52-week low of $170.67 and a 52-week high of $325.22. The firm has a market capitalization of $22.85 billion, a price-to-earnings ratio of 56.09, a PEG ratio of 3.62 and a beta of 1.26. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same period in the previous year, the firm posted $0.73 earnings per share. The business’s revenue was up 28.8% on a year-over-year basis. Sell-side analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on PODD shares. Raymond James reiterated an “outperform” rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 price objective for the company in a report on Tuesday, May 13th. Citigroup boosted their target price on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a report on Monday, April 28th. Finally, Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $306.53.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.